Earnings Watch: Margin squeeze, hiring freeze, and crisis mode Earnings Watch: Margin squeeze, hiring freeze, and crisis mode Earnings Watch: Margin squeeze, hiring freeze, and crisis mode

Earnings Watch: Margin squeeze, hiring freeze, and crisis mode

Equities 10 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  Yesterday's earnings releases from H&M, Nike, and Micron added more evidence to our hypothesis that the market is underestimating the margin squeeze that is unfolding at rapid speed. The cost-of-living crisis suppressing demand and rising wages impacting input costs are a dangerous cocktail for many companies including Apple that is lowering its production of iPhones to align with the lower demand. Meta also announced a hiring freeze and potential restructurings highlighting the deteriorating environment. The Q3 earnings season will most likely be a nasty surprise for many investors and analysts, and will likely trigger downgrades and lower price targets adding the next negative dynamic to the equity market.

Warnings signs from H&M, Nike, and Micron

If investors were hoping for good earnings news yesterday ahead of the Q3 earnings season that starts in two weeks they were left disappointed, or maybe even terrified. H&M and Nike both delivered operating margins below estimates as input costs are soaring, and H&M is going as far now as introducing charging for online returns suggesting the Swedish fashion retailer is under pressure. Nike delivered a small positive surprise on revenue but missed on gross margin by 1.1%-points filtering all the way through to FY23 Q1 EPS of $0.93 vs $1.16 a year ago. But two things in Nike’s results must have terrified investors. The company’s inventory levels continued to rise sharply suggesting terrible supply chain management and the company said that it would aggressively begin to reduce inventory in the current quarter. The US sports retailer expect gross margin to decline by 3.5-4%-points in their Q2 as a result of reducing inventory at an accelerated pace.

The weak results from H&M and Nike was not a big surprise to us as we have highlighted many times on our Saxo Market Call podcast and in equity notes that the energy shock is causing a cost-of-living crisis that is severely impacting consumption. But the outlook from Micron Technology was the big shocker as the memory chip manufacturer is guidance FY23 Q1 revenue of $4-4.5bn vs est. $6bn and adjusted gross margin in their Q1 of 24-28% vs est. 33.6%. We knew about the impact from the cost-of-living crisis and the signals from memory chip manufacturers have increasingly been bad, but this slowdown is dramatic and pointing towards rapidly deteriorating demand for consumer electronics. That is also why we warned about Apple’s earnings in our equity note yesterday, and that it is likely to impact the entire market sentiment and overall Q3 earnings season.

Finally, Meta announced yesterday that it is implementing a complete hiring freeze and that restructurings are under way. The technology company is under pressure in its advertising business from the data privacy update in iOS and slowing marketing demand as companies are cutting costs. On top of that, Meta is spending $10-12bn annualized on its Metaverse which is likely insanely expensive in the current energy shock with high electricity prices and venturing into a new platform might also not be the first priority of most companies these days.

Analysts are living in an alternative earnings universe

Consensus estimates for Q3 EPS in S&P 500 are still pointing toward q/q growth and as we wrote in yesterday’s note this equates to new record profit margin when we factor in consensus estimates for revenue which is set to decline. To us things are not adding up any longer and we expect revenue to continue increasing or being flat while EPS will take a big hit reducing the net profit margin in the S&P 500 by around 1%-point to 11.7%. Rising input costs now coming from wages which is the biggest operational expense item will drastically reduce margins in the upcoming earnings season and guidance will be uncertainty and weak from many companies. This will likely lead to a lot of downgrades and as we said many times recently trigger the next negative dynamic in the equity market leading to further declines.

Next week’s earnings

The list below highlights the most important earnings releases next week. Our focus will be on earnings from Biogen and Tesco. With the excellent news three days ago from Biogen and its Japanese partner Eisai that it has a treatment that slows Alzheimer’s in a large phase 3 trial, we expect Biogen to more about the potential for this drug if it is approved in the future. The news about this Alzheimer’s treatment is generally a great news for biotechnology investors that have suffered this year, but it also underscores why biotechnology should be part of long-term investors’ portfolios. Tesco is not usually a very interesting company but its FY23 1H result (ending 31 August) good be worth watching as Tesco has a large exposure to the UK consumer and as a grocery retailer can give insights into whether inflationary pressures are beginning to ease or not.

  • Tuesday: Biogen
  • Wednesday: Keurig Dr Pepper, Aeon, Lamb Weston, Tesco, RPM International
  • Thursday: Seven & I, Conagra Brands, Constellation Brands, McCormick & Co

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.